There are a number of biotech catalyst events left in 2022, including FDA/PDUFA events, data readouts, and biomedical meetings. See the table below highlighting the events in Dec:
CHRS - Coherus Biosciences
CHRS's asset Toripalimab has a PDUFA target action date of 12/23/2022 for the treatment of recurrent or metastatic Nasopharyngeal Carcinoma. Toripalimab previously received a CRL on 5/2/2022 and the BLA was resubmitted and accepted in July 2022.
Don't miss next weeks Catalyst Watchlist. Get our free weekly newsletter
*We never send you spam - unsubscribe anytime
Comments